Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma

PURPOSE: The majority of targeted personalized cancer therapies are effective only in part of the patients, and most of these drugs are excessively expensive. Therefore, methods are urgently required, which reveal already early during treatment, whether the therapy is effective. In the present repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Pachmann, Katharina, Camara, O., Kroll, T., Gajda, M., Gellner, A. K., Wotschadlo, J., Runnebaum, I. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155034/
https://www.ncbi.nlm.nih.gov/pubmed/21739182
http://dx.doi.org/10.1007/s00432-011-1000-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155034/
https://www.ncbi.nlm.nih.gov/pubmed/21739182
http://dx.doi.org/10.1007/s00432-011-1000-6

Ejemplares similares